10-Q: Bio-Path Holdings Faces Going Concern Doubt Amid Operational Pause

Bio-Path Holdings, a clinical-stage oncology and obesity drug developer, announced an operational pause and furloughed most employees due to critical capital constraints, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $4.6 million for the three months ended June 30, 2025, an increase from $1.9 million for the same period in 2024.
• The cash balance was $0 as of June 30, 2025, a significant decrease from $1.2 million at December 31, 2024.
• The accumulated deficit reached $125.0 million as of June 30, 2025.
• Implemented a company-wide operational pause and furloughed most employees on June 24, 2025, to conserve capital.
• The company's common stock was delisted from Nasdaq on February 14, 2025, and began trading on the OTCQB Venture Market on February 19, 2025.
• Ernst & Young LLP was dismissed as the independent registered public accounting firm on August 13, 2025, resulting in the Q2 2025 10-Q being unreviewed.
• Successfully completed the safety run-in for the triple combination of prexigebersen, decitabine, and venetoclax in the Phase 2 AML clinical study.
• Interim data for BP1001 (prexigebersen) Phase 2 AML trial (announced June 3, 2024) showed 75% complete remission (CR/CRh/CRi) in 20 evaluable newly diagnosed patients and 55% in 23 evaluable relapsed/refractory patients.
• Discontinued enrollment for the BP1002 Phase 1 clinical trial for refractory/relapsed lymphoma and chronic lymphocytic leukemia (CLL) on December 11, 2024, due to enrollment challenges and a crowded development landscape.
• Preclinical studies for BP1001-A showed potential as a treatment for obesity and Type 2 diabetes by increasing insulin sensitivity.

Sentiment

Score: 1

Explanation: The company is in a critical financial state with $0 cash, a significant accumulated deficit, and explicit substantial doubt about its ability to continue as a going concern. The operational pause, employee furloughs, Nasdaq delisting, and unreviewed financial statements indicate severe distress, despite some positive clinical data.

Positives

• Successfully completed the safety run-in for the triple combination of prexigebersen, decitabine, and venetoclax in the Phase 2 AML clinical study, with no dose limiting toxicities attributed to prexigebersen.
• Interim data for BP1001 (prexigebersen) Phase 2 AML trial showed promising efficacy, with 75% of 20 evaluable newly diagnosed patients achieving complete remission (CR/CRh/CRi) and 55% of 23 evaluable relapsed/refractory patients achieving CR/CRi/CRh.
• Preclinical studies for BP1001-A demonstrated potential to attenuate fatty acid-induced insulin resistance and restore insulin sensitivity, validating its potential as a treatment for obesity and Type 2 diabetes.
• Net cash used in operating activities decreased to $1.6 million for the six months ended June 30, 2025, from $4.3 million for the same period in 2024.

Negatives

• The cash balance was $0 as of June 30, 2025, indicating severe liquidity issues.
• The accumulated deficit increased significantly to $125.0 million as of June 30, 2025.
• Net loss for the three months ended June 30, 2025, increased to $4.6 million from $1.9 million for the same period in 2024.
• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient capital for the next 12 months.
• Implemented a company-wide operational pause and furloughed most employees to conserve capital, signaling a critical financial situation.
• The company's common stock was delisted from Nasdaq and now trades on the OTCQB Venture Market.
• The dismissal of Ernst & Young LLP as independent auditor and the unreviewed status of the Q2 2025 financial statements raise concerns about financial oversight and compliance.
• Discontinued enrollment for the BP1002 Phase 1 clinical trial for refractory/relapsed lymphoma and CLL due to enrollment challenges and a crowded development landscape.
• Total liabilities more than doubled to $7.9 million as of June 30, 2025, from $3.7 million as of December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to insufficient capital to fund operations for the next 12 months.
• The company needs substantial additional capital, and its inability to raise funds may force delays, reductions, or elimination of drug development and commercialization efforts.
• The pharmaceutical and biotechnology industry is highly competitive, impacting the company's ability to compete effectively.
• Clinical trials may be delayed or terminated, affecting drug candidate development.
• Reliance on third parties for manufacturing clinical drug supplies poses supply chain risks.
• The trading price of the common stock is volatile and thinly traded.
• The operational pause and employee furloughs may result in unintended consequences, such as loss of institutional knowledge, attrition beyond intended numbers, decreased morale, and difficulty pursuing new opportunities.
• The Q2 2025 10-Q has not been reviewed by an independent registered public accounting firm, which is a deficiency and may not fully comply with SEC requirements.
• Default on promissory notes could lead to immediate repayment at 150% of outstanding principal plus interest and default interest at 22% per annum, with potential conversion into common stock at a discounted price (65% of lowest bid price).

Future Outlook

The company expects to continue incurring significant operating losses and anticipates these losses may increase as drug development programs expand. It will require substantial additional capital to fund projected operating requirements, with no assurance that such capital will be available when needed or on favorable terms. The company may seek collaborations and license arrangements for its drug candidates. A molecular biomarker package is being developed to accompany prexigebersen treatment, aiming to identify patients with a genetic profile more likely to respond to the investigational treatment and improve program success probability.

Management Comments

• The Board is currently discussing and evaluating a course of action in light of the Company’s limited capital resources, such operational pause and the resignations of Peter H. Nielsen, Heath Cleaver and Aline Sherwood.

Industry Context

The company operates in the highly competitive pharmaceutical and biotechnology industry, focusing on oncology and obesity drug development. The discontinuation of the BP1002 trial for lymphoma/CLL due to a 'crowded development landscape' underscores the intense competition and challenges in niche indications. The shift to focus on obesity reflects a broader industry trend of diversifying pipelines. The company's severe liquidity issues and 'going concern' doubt are common challenges for clinical-stage biotech companies that have not yet commercialized products and are heavily reliant on external funding.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Significant negative impact due to Nasdaq delisting, stock trading on OTCQB, substantial doubt about going concern, increased net loss, and potential dilution from future capital raises or conversion of promissory notes at discounted prices.
• Employees: Most employees furloughed due to the operational pause, leading to job insecurity and potential loss of talent and institutional knowledge.
• Creditors (Promissory Note Lenders): Face risk of default, but also have potential for significant returns (150% repayment, 22% default interest, discounted stock conversion) if default occurs.
• Patients/Clinical Trial Participants: The operational pause and funding issues could delay or halt ongoing clinical trials, impacting the development of potential future treatments for serious diseases like AML and pancreatic cancer.

Next Steps

• Seek additional funding through debt financings and public or private equity offerings.
• Seek collaborations and license arrangements for drug candidates.
• Complete the remaining IND enabling study for BP1003.
• Actively work with an independent registered public accounting firm to remedy the deficiency of unreviewed financial statements and file an amendment to the Form 10-Q.
• The Board is discussing and evaluating a course of action in light of limited capital resources, operational pause, and management resignations.
• Make scheduled payments on promissory notes, with the first payment on the First Promissory Note due August 30, 2025, on the Second Promissory Note due September 30, 2025, and on the April 2025 Promissory Note due October 15, 2025.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by $0 cash, a substantial accumulated deficit, and explicit 'going concern' doubt. The operational pause, mass furloughs, Nasdaq delisting, and unreviewed financials signal an imminent risk of bankruptcy or significant restructuring that would heavily dilute existing shareholders. While some clinical data is positive, the financial viability to advance these programs is critically compromised, making the stock a high-risk, speculative investment with significant downside.

Keywords

Bio-Path Holdings, BPTH, oncology, RNAi, nanoparticle, drug development, clinical trials, AML, prexigebersen, BP1002, BP1003, BP1001-A, obesity, Type 2 diabetes, going concern, capital raise, Nasdaq delisting, biotechnology, pharmaceutical